NCCN 17th Annual Conference



Guidelines clarify role of PET in HL

Jen Smith Read Article
Published: 03/23/12

Richard T. Hoppe, MD

Updated NCCN guidelines suggest that PET imaging is useful for staging but unnecessary as surveillance in patients with Hodgkin lymphoma (HL). The guidelines recommend PET scans to evaluate initial staging and assess treatment response at restaging. They also cite several studies showing the prognostic value of early interim PET scans in HL patients with advanced or extranodal disease. However, the guidelines advise against using PET scans as routine surveillance, due to the risk of . . . [Read Article]

Despite long DFS, HCL patients need monitoring

Jen Smith Read Article
Published: 03/22/12

Andrew D. Zelenetz, MD, PhD

Current survival rates in hairy cell leukemia (HCL) are “superb,” but physicians must not let this lull them into a false sense of security, according to a speaker at the recent NCCN meeting. The preferred drugs for HCL—cladribine and pentostatin—elicit high rates of complete response that can translate into more than a decade of disease-free survival, said speaker Andrew D. Zelenetz, MD, PhD, of Memorial Sloan-Kettering Cancer Center in New York. But HCL patients are still at risk . . . [Read Article]

Experts outline approach to risk stratification in ALL

Jen Smith Read Article
Published: 03/21/12

Session at the NCCN conference

In a new set of guidelines, NCCN panelists give physicians a clear direction for stratifying non-pediatric patients with acute lymphoblastic leukemia (ALL). There is still some debate surrounding risk stratification in ALL. But the new NCCN guidelines for the disease suggest optimal risk stratification involves separating patients according to Ph status and age. Patrick A. Brown, MD, discussed this recommendation at the recent NCCN conference in Hollywood, Florida. [Read Article]

Poor outcomes prompt new guidelines

Jen Smith Read Article
Published: 03/20/12

Peter F. Coccia, MD

In light of the poor outcomes observed in adolescents and young adults (AYAs) with cancer, the NCCN has released new supportive care guidelines for this patient population. AYA patients are defined as individuals who are 15 to 39 years of age at initial cancer diagnosis. And these patients often fare worse than older oncology patients and their pediatric counterparts, according to Peter F. Coccia, MD, of The Nebraska Medical Center. “[T]here has been dismal, dismal progress . . . [Read Article]

Guideline endorses alemtuzumab for T-PLL

Jen Smith Read Article
Published: 03/19/12

Leo I. Gordon, MD

Intravenous alemtuzumab is the preferred treatment for T-cell prolymphocytic leukemia (T-PLL), according to a new guideline from NCCN. The guideline, added to the latest edition of NCCN’s Non-Hodgkin’s Lymphomas guidelines, recommends alemtuzumab alone or an alemtuzumab-containing regimen as initial therapy for patients with symptomatic T-PLL. The guideline also highlights the importance of administering the drug intravenously rather than subcutaneously.  [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}